Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1121008

Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings


Ramadža, Danijela Petković; Zekušić, Marija; Žigman, Tamara; Škaričić, Ana; Bogdanić, Ana; Mustać, Gordana; Bošnjak-Nađ, Katarina; Ozretić, David; Ohno, Kousaku; Fumić, Ksenija; Barić, Ivo
Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings // European Journal of Paediatric Neurology, 32 (2021), 66-72 doi:10.1016/j.ejpn.2021.03.013 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1121008 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings

Autori
Ramadža, Danijela Petković ; Zekušić, Marija ; Žigman, Tamara ; Škaričić, Ana ; Bogdanić, Ana ; Mustać, Gordana ; Bošnjak-Nađ, Katarina ; Ozretić, David ; Ohno, Kousaku ; Fumić, Ksenija ; Barić, Ivo

Izvornik
European Journal of Paediatric Neurology (1090-3798) 32 (2021); 66-72

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Gaucher disease type 3, Neuronopathic form, Ambroxol, Pharmacological chaperone

Sažetak
Gaucher disease type 3 (GD3) is a severely debilitating disorder characterized by multisystemic manifestations and neurodegeneration. Enzyme replacement therapy alleviates visceral signs and symptoms but has no effect on neurological features. Ambroxol has been suggested as an enzyme enhancement agent. Some studies have confirmed its effectiveness in preventing the progression of neurological manifestations of neuronopathic Gaucher disease. In this study, we report two GD3 siblings in whom ambroxol combined with enzyme replacement therapy was initiated at different stages of the disease. We demonstrate the enzyme enhancement effect of ambroxol on L444P/H225Q ; D409H glucocerebrosidase activity through results of fibroblast studies and long-term clinical outcomes of the two patients. The sibling diagnosed at the age of four-and-a-half years with significant neurological involvement manifested relatively rapid improvement on ambroxol treatment, followed by stabilization of further course. The younger sibling, in whom the treatment was started at seven weeks, displayed attention deficit and low average cognitive functioning at the age of seven years, but did not manifest other neurological symptoms. The difference in neurological outcomes indicates that ambroxol delayed or even halted the evolution of neurological manifestations in the younger sibling. This observation suggests that early initiation of ambroxol treatment may arrest neurological involvement in some GD3 patients.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Ustanove:
Klinički bolnički centar Zagreb

Profili:

Avatar Url Ivo Barić (autor)

Avatar Url Ksenija Fumić (autor)

Avatar Url David Ozretić (autor)

Avatar Url Marija Zekušić (autor)

Citiraj ovu publikaciju

Ramadža, Danijela Petković; Zekušić, Marija; Žigman, Tamara; Škaričić, Ana; Bogdanić, Ana; Mustać, Gordana; Bošnjak-Nađ, Katarina; Ozretić, David; Ohno, Kousaku; Fumić, Ksenija; Barić, Ivo
Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings // European Journal of Paediatric Neurology, 32 (2021), 66-72 doi:10.1016/j.ejpn.2021.03.013 (međunarodna recenzija, članak, znanstveni)
Ramadža, D., Zekušić, M., Žigman, T., Škaričić, A., Bogdanić, A., Mustać, G., Bošnjak-Nađ, K., Ozretić, D., Ohno, K., Fumić, K. & Barić, I. (2021) Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings. European Journal of Paediatric Neurology, 32, 66-72 doi:10.1016/j.ejpn.2021.03.013.
@article{article, year = {2021}, pages = {66-72}, DOI = {10.1016/j.ejpn.2021.03.013}, keywords = {Gaucher disease type 3, Neuronopathic form, Ambroxol, Pharmacological chaperone}, journal = {European Journal of Paediatric Neurology}, doi = {10.1016/j.ejpn.2021.03.013}, volume = {32}, issn = {1090-3798}, title = {Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings}, keyword = {Gaucher disease type 3, Neuronopathic form, Ambroxol, Pharmacological chaperone} }
@article{article, year = {2021}, pages = {66-72}, DOI = {10.1016/j.ejpn.2021.03.013}, keywords = {Gaucher disease type 3, Neuronopathic form, Ambroxol, Pharmacological chaperone}, journal = {European Journal of Paediatric Neurology}, doi = {10.1016/j.ejpn.2021.03.013}, volume = {32}, issn = {1090-3798}, title = {Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings}, keyword = {Gaucher disease type 3, Neuronopathic form, Ambroxol, Pharmacological chaperone} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font